[
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why",
    "summary": "In the closing of the recent trading day, AbbVie (ABBV) stood at $236.56, denoting a -3.2% move from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=a625c0958258418062e6af0f40be1a7ac40d0946a9ab61e9e9fad91af10edeac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759441502,
      "headline": "AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why",
      "id": 136959993,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, AbbVie (ABBV) stood at $236.56, denoting a -3.2% move from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=a625c0958258418062e6af0f40be1a7ac40d0946a9ab61e9e9fad91af10edeac"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Thursday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=1975e99a7698eb064df9a4727bfd2e61f65eece573617726bd8431b1cb35b579",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759422660,
      "headline": "AbbVie Inc. stock underperforms Thursday when compared to competitors",
      "id": 136995800,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=1975e99a7698eb064df9a4727bfd2e61f65eece573617726bd8431b1cb35b579"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market News for Oct 2, 2025",
    "summary": "Wall Street closed higher on Wednesday, driven by healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=486ea7a29c84b8ec9f1ceacc7382816e27d56a559f3f203c734747cf35b7a770",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759411380,
      "headline": "Stock Market News for Oct 2, 2025",
      "id": 136959994,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Wall Street closed higher on Wednesday, driven by healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=486ea7a29c84b8ec9f1ceacc7382816e27d56a559f3f203c734747cf35b7a770"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Host Third-Quarter 2025 Earnings Conference Call",
    "summary": "AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
    "url": "https://finnhub.io/api/news?id=71174df0c2881997ef358e0fe6b8cdb1fa0124c2c0bffd3c06a40ac37bcb866a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759406400,
      "headline": "AbbVie to Host Third-Quarter 2025 Earnings Conference Call",
      "id": 136955344,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) will announce its third-quarter 2025 financial results on Friday, October 31, 2025, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
      "url": "https://finnhub.io/api/news?id=71174df0c2881997ef358e0fe6b8cdb1fa0124c2c0bffd3c06a40ac37bcb866a"
    }
  },
  {
    "ts": null,
    "headline": "Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease",
    "summary": "Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for ABBV-CLS-628, an investigational therapy for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). ABBV-CLS-628, an anti-PAPP-A monoclonal antibody, was developed by Calico in collaboration with AbbVie Inc. The therapy is current",
    "url": "https://finnhub.io/api/news?id=74bd4ae96cc07b4e3435cf8a07d58eb946564e8202fd31698f539c5e16319ec0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759406400,
      "headline": "Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease",
      "id": 136955249,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for ABBV-CLS-628, an investigational therapy for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). ABBV-CLS-628, an anti-PAPP-A monoclonal antibody, was developed by Calico in collaboration with AbbVie Inc. The therapy is current",
      "url": "https://finnhub.io/api/news?id=74bd4ae96cc07b4e3435cf8a07d58eb946564e8202fd31698f539c5e16319ec0"
    }
  },
  {
    "ts": null,
    "headline": "Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations",
    "summary": "Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (\"Defence\" or the \"Company\"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D, biotech innovation, and commercial manufacturing, with a proven track record in building and leading.",
    "url": "https://finnhub.io/api/news?id=a9101a63969afe0caa73ecf665b68e85c30395d26101a31835aa105989d7e420",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759389300,
      "headline": "Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations",
      "id": 136955345,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Montreal, Quebec--(Newsfile Corp. - October 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (\"Defence\" or the \"Company\"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and Operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D, biotech innovation, and commercial manufacturing, with a proven track record in building and leading.",
      "url": "https://finnhub.io/api/news?id=a9101a63969afe0caa73ecf665b68e85c30395d26101a31835aa105989d7e420"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie (ABBV) Advances Parkinson’s Treatment With Tavapadon NDA",
    "summary": "AbbVie Inc. (NYSE:ABBV) ranks among the top picks for a retirement portfolio. The FDA received a New Drug Application from AbbVie Inc. (NYSE:ABBV) on September 26 for tavapadon, an experimental oral medication used once daily to treat Parkinson’s disease. The application is based on data from the Phase 3 TEMPO clinical trial, which assessed tavapadon […]",
    "url": "https://finnhub.io/api/news?id=d12dafa6002c5c426453f7486e4b6325c160677a86cefc84398bc9696cafa7c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759388133,
      "headline": "AbbVie (ABBV) Advances Parkinson’s Treatment With Tavapadon NDA",
      "id": 136955346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) ranks among the top picks for a retirement portfolio. The FDA received a New Drug Application from AbbVie Inc. (NYSE:ABBV) on September 26 for tavapadon, an experimental oral medication used once daily to treat Parkinson’s disease. The application is based on data from the Phase 3 TEMPO clinical trial, which assessed tavapadon […]",
      "url": "https://finnhub.io/api/news?id=d12dafa6002c5c426453f7486e4b6325c160677a86cefc84398bc9696cafa7c7"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: If You're Considering Selling, Buy QDVO Instead",
    "summary": "SCHD offers reliable dividends, defensive sector allocation, and a strong track record. Click here to find out why SCHD ETF is a Buy.",
    "url": "https://finnhub.io/api/news?id=90462e3cb84e6fbd454dc8a373fb57ed8b92c41ddbd5514290b867c60aa67782",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759386600,
      "headline": "SCHD: If You're Considering Selling, Buy QDVO Instead",
      "id": 136954634,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/520290362/image_520290362.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "SCHD offers reliable dividends, defensive sector allocation, and a strong track record. Click here to find out why SCHD ETF is a Buy.",
      "url": "https://finnhub.io/api/news?id=90462e3cb84e6fbd454dc8a373fb57ed8b92c41ddbd5514290b867c60aa67782"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance",
    "summary": "AbbVie Inc. (NYSE:ABBV) ranks among the stocks with low beta that can beat market volatility. On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had […]",
    "url": "https://finnhub.io/api/news?id=0b814482f638a137890b16d2ad99312bd5817ec146ea6b6b4d0b893e1c925de9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759385321,
      "headline": "Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance",
      "id": 136955347,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) ranks among the stocks with low beta that can beat market volatility. On September 24, Leerink Partners maintained its Outperform rating on AbbVie Inc. (NYSE:ABBV) and raised its price target on the company’s shares from $210 to $243. The increase comes after AbbVie Inc. (NYSE:ABBV) announced on September 11 that it had […]",
      "url": "https://finnhub.io/api/news?id=0b814482f638a137890b16d2ad99312bd5817ec146ea6b6b4d0b893e1c925de9"
    }
  },
  {
    "ts": null,
    "headline": "HSBC Downgrades AbbVie (ABBV)",
    "summary": "HSBC Downgrades AbbVie (ABBV)",
    "url": "https://finnhub.io/api/news?id=1f94ae07f120770fd78eabd816e6c1242fc4cd711a7fcd01465644d691f5b6a5",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759363570,
      "headline": "HSBC Downgrades AbbVie (ABBV)",
      "id": 136950866,
      "image": "",
      "related": "ABBV",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1f94ae07f120770fd78eabd816e6c1242fc4cd711a7fcd01465644d691f5b6a5"
    }
  }
]